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Abstract
The conduct of clinical trials in the UK has been affected by the recent introduction of managed
clinical networks, clinical research networks and rigorous governance regulations. This
commentary considers the challenges that these changes have posed for clinical triallists in the UK,
based on experiences derived in the conduct of a multicentre neonatal clinical trial under the
conditions that now prevail. We conclude that the considerable skills and knowledge that are now
required to be an effective Principal Investigator should be recognised and that application
processes, including issuing honorary contracts, should be simplified and centralised.
Introduction
A recent paper by Vickers and Scardino in Trials [1] dis-
cussed the barriers facing patient accrual into cancer trials,
focussing particularly on finance and regulatory issues
and the heterogeneity of cancer patients. Similar chal-
lenges to performing clinical trials in the United States
were further described by Crawford and Tangen[2]. In this
commentary, we draw attention to three changes, which
have recently impacted on the management and conduct
of clinical trials in general: (a) the formation of managed
clinical networks (MCNs), (b) clinical research networks
(CRNs); these major organisational changes coincided
with a third, (c) the introduction of rigorous governance
regulations. An unanticipated consequence of these three
developments was an increase in the complexity involved
in setting up and conducting clinical trials in the UK. This
complexity is difficult enough for experienced triallists
and the practical nature of clinical research is that success-
ful trials need to be undertaken in a clinical environment
and can require the involvement of district general hospi-
tal clinical specialists We have drawn on our experiences
with a different group of patients, newborn babies, which
shares some of the issues identified by Vickers and
Scardino, but highlights other factors, which were not
anticipated but which are relevant to all patient groups
and which are likely to affect other clinical trials in the UK.
These interdependent developments are described more
fully below with some suggestions for improving the
process.
The Effect of Managed Clinical Networks (MCNs) on 
Clinical Trials
These networks of health staff and organisations, ranging
from primary to tertiary health care, are intended to
ensure that high quality clinically effective services are
fairly distributed and that health costs are reduced[3].
Their introduction raised a number of issues.
By developing as a MCN, a service, which is accessed
locally, can make a range of sub-specialties available to all
and so improve the quality of patient care. Over the years,
more and more sub-specialties across the UK have devel-
oped MCNs, ranging from coronary heart disease, stroke
and diabetes. Neonatal MCNs were established across
England in 2004[4]. Against a backdrop of the tremen-
dous human cost and financial burden of preterm birth
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and its consequences, estimated at an annual cost of £939
million to the UK[5], they were intended to provide a
structure and organisation for highly specialised perinatal
care, allowing equitable access for all very sick infants with
the intention of improving the quality of their care gener-
ally. This resulted in the designation of regional hospitals
for the care of the sickest and most immature infants,
sometimes at considerable distance from the local hospi-
tal where their mothers had booked for obstetric care.
Such babies are then transferred back to their local mater-
nity hospitals when clinically stable.
From a clinical trial perspective, the specialist therapy that
is being tested is often only available at the regional cen-
tre. This happened in several successful neonatal trials,
e.g. the TOBY study of total body hypothermia for asphyx-
iated term babies [6] and the UK study of extracorporeal
membrane oxygenation[7], as well as in the TIPIT trial[8],
a randomised controlled trial where thyroxine supple-
mentation was given to babies born below 28 weeks' ges-
tation to test the hypothesis that such supplementation
improves brain growth. Recruitment to TIPIT took place at
five regional recruiting centres during the first five days of
life. Recruited babies, whose mothers had booked else-
where for their maternity care, were then transferred back
to 24 other non-recruiting local hospitals within the
MCN, known in clinical trial jargon as "step-down sites".
TIPIT, like other such studies, involved later trial-specific
assessments and continuation of the trial intervention at
the local hospitals. The regulatory processes for this are
complex and considered below.
Effect of Clinical Research Networks (CRNs) on clinical 
trials
CRNs were developed to support and coordinate high
quality clinical research and to facilitate the conduct of
clinical trials and other studies within the National Health
Service (NHS) [9]. The National Institute for Health
Research (NIHR) Comprehensive Clinical Research Net-
work (CCRN) was created as part of the government's
research and development strategy, "Best Research for Best
Health" to provide a world-class infrastructure for clinical
trials in all areas of disease and clinical need within the
NHS[9]. The NIHR CCRN works together with the six
Topic Specific CRNs and a Primary Care Research Net-
work to support a national portfolio of clinical trials and
other studies. The network that we had most involvement
with was the Medicines for Children Research Network
(MCRN). The MCRN was established in 2006 to improve
the clinical research environment for children with a
stated aim "to facilitate the conduct of randomised pro-
spective trials and other well-designed studies of medi-
cines for children, including those for prevention,
diagnosis and treatment" [10]. A similar function is pro-
vided by CRN for other patient groups [9].
If a trial involves an unlicensed medicine without support
by a large pharmaceutical company, considerable
resources are required. There needs to be intensive input
from trust pharmacists and trust R&D (Research and
Development) departments to deal with manufacturing
the investigational medicinal product (IMP), its quality
control, blinding and dispensing. This requires considera-
ble specialist knowledge and resources. Furthermore, a
clinical medicinal trial requires sponsors, usually a univer-
sity and an NHS trust, who are responsible for its design,
conduct, recording and reporting.
TIPIT was the first clinical trial to benefit from the MCRN
since its establishment in 2006[8]. The catchment area for
the main hospital for TIPIT included several NHS regions
and managed clinical networks to which recruited babies
were transferred back. Several local MCRN research net-
works provided invaluable assistance with site initiations,
gaining separate ethical and R&D approvals and honorary
contracts for investigators in all 29 trusts involved in the
trial. Nursing staff employed by the MCRN also assisted in
trial promotion to relevant nursing, medical and R&D
staff and provided some pharmacy support. The MCRN
also assisted sponsors in the monitoring of GCP compli-
ance during the conduct of the trial and supported trust
pharmacies and TIPIT successfully underwent three
MHRA inspections.
Regulation of clinical trials and step-down sites
At the same time as the networks described above were
being set up, a rigorous regulatory framework was estab-
lished in the UK. The legal framework for conducting clin-
ical trials was prepared under Directive 2001/20/EC, the
European Union Clinical Trials Directive (EUCTD) [11].
The EUCTD established specific provisions for the con-
duct of clinical trials and implementation of Good Clini-
cal Practice (GCP)[12]. The EUCTD was transposed into
UK law as the Medicines for Human Use (Clinical Trials)
Regulations on the 1st May 2004 (SI 2004/1031) [13]. The
Medicines for Human Use (Clinical Trial) Amendment
Regulations (SI 2006/1928) came into force on 29 August
2006 to incorporate the GCP Directives[14]. In the UK, all
clinical trials involving medicinal products must now
include stringent internal regulation and adhere closely to
these guidelines.
These changes, which were instituted between 2004 and
2006, were aimed at promoting the scientific value of clin-
ical trials. However, they have increased enormously the
complexities. The impact of MCNs on the conduct of trials
has been significant particularly in terms of legislative reg-
ulation. Now all step-down sites within a MCN require
separate ethical and R&D approval even if no patients
from that hospital are actually recruited into the trial.Trials 2009, 10:100 http://www.trialsjournal.com/content/10/1/100
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Our own experience was that since babies were not infre-
quently transferred from one neonatal network to
another, sometimes a hundred miles away or more, it was
not possible to predict all the hospitals from where poten-
tial trial subjects might come. As there was no centralised
system for approval by individual trusts' R&D commit-
tees, we had to apply directly to every trust R&D commit-
tee within and outside the region, guessing at the
likelihood of a baby being transferred to that hospital. The
use of step-down sites gave rise to particularly complex
arrangements. In TIPIT's case, each trust had to apply to
the National Research Ethics Service (NRES)[15] for full
Site Specific Assessment (SSA) Approval for trial medica-
tions to be continued and follow up assessments to be
done. (Under the complicated terms of NRES approvals,
the final trial assessment does not require a SSA if the trial
intervention is not required, but application for SSA
exemption must still be approved by NRES. In addition,
individual step down sites require separate approval by
their own R&D committees. These are discussed further
below.)
One way that the national system has progressed is
through the establishment of a coordinated system for
gaining approval for taking part in a clinical trial. Previ-
ously, each hospital authority had to be approached indi-
vidually for ethical approval. This has been replaced by a
more streamlined system. The NIHR Coordinated System
for gaining trial approvals was set up in November 2008
and incorporated two regulatory agencies, the Medicines
and Healthcare Products Regulatory Agency (MHRA)[14]
and NRES[15].
In an attempt to simplify the application process for
approval for a clinical trial, an Integrated Research Appli-
cation System (IRAS)[16] was established to capture all
relevant information in a single application process.
Although IRAS provides a single ethical committee appli-
cation process, there is still no centralised system for
approval by trust R&D committees and multi-centred tri-
als still require separate approvals from individual trusts.
Approval of clinical trials by individual R&D departments
in the UK varies considerably and is generally slow: two
recent studies reported a median delay of 44 days[17,18]:
only half the R&D departments surveyed used efficient
methods such as online R&D application forms.
The status of each site needs to be specified. If recruitment,
the trial intervention and follow-up are to be undertaken
on that site, full approval is required and a Principal
Investigator (PI) is needed. The PI may not have been
involved in the conception of the study but is required to
have a deep knowledge of the protocol, be available for 24
hour adverse event reporting, and needs to be trained in
GCP [12]. Alternatively, if only the trial's stated follow-up
aspects of care are to be undertaken, the specified site may
apply for SSA exemption and a 'Named Clinician' needs to
be identified as the responsible person responsible for the
study at that site. This individual is responsible for the
study at the site and usually a NHS clinician.
Most PIs are at present unlikely to see taking part in trials
as their main role. Particularly at step-down sites, our
experience was that some clinicians were so daunted that
they declined to even start the process. This was in keeping
with the observations of other triallists, who have
reported that the impact of administrative burdens
imposed in UK to the EU Clinical Trials Directive even
resulted in the failure of some trials[19,20]. This is clearly
not in the spirit of promoting a sound evidence base for
clinical practice when the existing evidence is insufficient.
The observation leads us to the suggestion that, because of
the regulatory complexities and the importance of the
establishment of a sound evidence base for clinical prac-
tice, one of each group of clinicians takes on the role of
lead investigator for all trials that are done on patients in
that department. This approach would be analogous to
the development of specific expertise in either manage-
ment or teaching, which are recognised for clinical excel-
lence awards.
Participating trusts also require honorary contracts for all
research personnel. To simplify the process, the NIHR
established honorary research passports [21], but these
are only accepted at the discretion of individual trusts and
still have to be submitted individually to each trust's
human resource department. In the TIPIT study, 24 out of
the 29 trusts within the MCN did not accept the standard
research passport and required their own individual appli-
cation and assessment involving a detailed occupational
health assessment prior to issuing the honorary contracts.
Other researchers have also reported that they were
required to obtain unnecessary honorary contracts and
Criminal Record Bureau checks during the process of
obtaining R&D approvals[22,23]. It would be enormously
helpful if the proposed "research passports", piloted in
Manchester and promoted by the R&D forum and
UKCRN, were adopted by all trusts.
Discussion
The effects of these three recent developments on the con-
duct of clinical trials were experienced to full effect in the
course of the establishment and management of TIPIT [8],
which was entirely funded through a Medical Research
Council fellowship. This fellowship had the primary aim
of providing training for an individual in research tech-
niques and the largest part of the grant was for salary with
a relatively small amount available for running costs
(£10,000 per annum). However, for training to be effec-
tive, the study that the research fellow is involved in needsTrials 2009, 10:100 http://www.trialsjournal.com/content/10/1/100
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Flowchart for setting up and conducting a multi centred clinical trial Figure 1
Flowchart for setting up and conducting a multi centred clinical trial.
Full approval – allows recruitment, the trial 
intervention and follow-up to be undertaken on 
the specified site. This requires (i) the 
appointment of a Principal Investigator who has 
to undergo GCP training, (ii)  Local Research 
Ethics Approval (LREC), (iii)  SSA recognition, 
(iv) local R&D approval, and (v) local 
pharmacy set up. 
SSA exempt approval – allows only the stated 
follow-up aspects of a baby’s care to be 
undertaken on the specified site and requires a 
‘Named Clinician’ to be identified as the 
responsible person at the site. The site does not 
require LREC SSA approval but requires Trust 
R&D approval.
Determine type of approval required for step-down sites involved in the transfer of recruited baby. 
Complete Clinical Trials Application from MHRA & Ethics Submission from NRES
This application process can now be integrated via the Integrated Research Application System (IRAS)
Obtain R&D approval from main sponsor
Identify a Principal Investigator or Named Clinician at each step down site and establish collaboration with the MCRN LRN team to
promote study to nursing, medical and R&D staff at local units
Final peer reviewed protocol with early collaborations with the CRN, R&D, Clinical Trials unit, and pharmacy leads
Submit for either LREC SSA approvals or contact MREC to approve Named Clinician and list of SSA exempt follow up assessments
Submit full R&D approvals for all step-down sites
Collaboration with CRNs to assist in submission of individual Trust R&D approvals and honorary contract applications  for  investigators
Develop transfer packs with appropriate Standard Operating procedures for recruiting and non-recruiting centres
Ensure regular meetings between all study collaborators, the research network team and investigators.Trials 2009, 10:100 http://www.trialsjournal.com/content/10/1/100
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to be worthwhile and robust. In this case, the research fel-
low was to gain the competences required to establish and
run a high quality multi-centre randomised controlled
trial and to analyse its complex results. There was there-
fore heavy reliance on NHS resources and those of the
UK's developing MCN and CRN infrastructure. This com-
bination resulted in a successful trial, which completed
recruitment ahead of its predicted time at a low cost to the
MRC.
Although modern legislation has improved the scientific
rigour of such studies, it has also added to their intricacy.
MCNs, while improving the effectiveness of clinical care,
have added to the complexities of running an effective
clinical trial. It is clear that meeting all the new regulatory
requirements and taking account of the effect of managed
clinical networks (particularly step-down units) on clini-
cal trials is outside the present experience of even experi-
enced triallists. However, CRNs have improved the cost
effectiveness of trials through the provision of an estab-
lished, separately funded network, which is able to assist
in patient accrual, promotion of the trial to nursing, med-
ical and R&D staff and in the trial's day to day manage-
ment. Our experience of a publicly-funded trial with a
limited budget and limited staff was that the MCRN's sup-
port role was crucial. The process of setting up and con-
ducting a multicentred clinical trial under the current
regulatory system is described in Figure 1.
Conclusion
We conclude with several recommendations. Firstly, that
there should be further development of the infrastructure
to support clinical trials within the framework of MCNs
and CRNs. This should aim to achieve governance in a
timely and effective manner, but with less bureaucracy.
This could be achieved by the acceptance by each trust of
a common process. Secondly, triallists need to establish
collaborations with relevant departments and agencies
early in planning, which should include the relevant
research and clinical networks. We would urge clinical
research networks to provide more support with the
bureaucracy associated with the establishment and pro-
gression of a clinical trial. Thirdly, application processes,
including the provision of honorary contracts, should be
simplified and centralised. Finally, the competences
required to be an effective PI should be given managerial
recognition.
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